- Ipamorelin is a selective ghrelin-receptor agonist studied for stimulating pulsatile growth-hormone release with minimal effect on cortisol or prolactin in the systems examined.
- Human data on ipamorelin is limited and dated, and sex-stratified reporting is essentially absent, so claims about its effects in women are extrapolated rather than measured.
- The growth-hormone axis interacts with estrogen, but no study characterizes that interaction for ipamorelin, leaving cycle, hormonal, and menopause questions unstudied.
Ipamorelin has a reputation among research peptides for being clean, and in mechanistic terms that reputation is earned. It is a synthetic pentapeptide and a selective agonist of the ghrelin, or growth-hormone secretagogue, receptor (GHS-R). Its selectivity is genuinely its defining feature. What that selectivity does not fix is the field's oldest problem: the human data is thin, and the sex-stratified data is close to nonexistent.
Why it is called selective
In preclinical and in-vitro models, ipamorelin has been studied for its stimulation of pulsatile growth-hormone-release pathways. What sets it apart is that it engages the GHS receptor with minimal effect on cortisol or prolactin signaling in the systems examined. Researchers characterizing secretagogue selectivity have used it precisely because it isolates one pathway with relatively little cross-activity.
For a performance and longevity catalog, that selectivity is the appeal: it lets investigators probe growth-hormone signaling with fewer confounding effects. It is a statement about mechanism and specificity, not about outcomes in people.
The dosing conventions are male-weighted
Ipamorelin's research status is early, its human data is limited and old, and no established therapeutic dose exists. That matters for women in a specific way. When dosing conventions circulate for a compound whose few human studies skewed toward male or mixed populations without sex analysis, those conventions are not female-derived. They are defaults built on data that never answered the female question.
Where dose figures appear for ipamorelin, they come from early studies and are reported for reference only. They are not female-specific and not a protocol. This site does not publish personal dosing, and nothing here is medical advice.
The female-evidence gap
The growth-hormone axis is not sex-neutral; it interacts with estrogen. So a secretagogue acting on that axis invites a female-physiology question. For ipamorelin, no study characterizes that interaction, and the broader female record is largely empty.
- Menstrual cycle: no cycle-interaction data has been indexed.
- Hormonal interactions: the growth-hormone axis interacts with estrogen, but no study characterizes this for ipamorelin in women.
- Perimenopause and menopause: no data in perimenopausal or menopausal populations.
- Pregnancy and lactation: no data exists, and absence of harm data is not evidence of safety.
- Sex differences: few studies included female subjects, and none reported sex-stratified outcomes.
Ipamorelin is supplied for in-vitro and laboratory research only. Compared with oral secretagogues that at least saw women enrolled in some trials, ipamorelin's female record is more sparse still: few female subjects, no sex-stratified reporting. The ipamorelin compound profile shows exactly how that thin record derives its evidence grade, and why, for women, the most accurate word remains unstudied.